Covered recipient · General Payments record
ELIZABETH M READ
Allopathic & Osteopathic Physicians Obstetrics & Gynecology
General Payments · PY2018–2024
$2,005.63
- Reported across 114 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $308.60 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Astellas Pharma US Inc | $74.23 | 4 |
| PFIZER INC. | $74.14 | 4 |
| Sumitomo Pharma America, Inc. | $41.66 | 2 |
| MAYNE PHARMA COMMERCIAL LLC | $27.68 | 1 |
| Sage Therapeutics, Inc. | $22.69 | 1 |
| Organon LLC | $22.49 | 1 |
| Exeltis, USA Inc. | $17.27 | 1 |
| Novo Nordisk AS | $14.84 | 1 |
| Genentech, Inc. | $13.60 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Astellas Pharma US Inc | $16.29 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139278574 | CMS |
| Astellas Pharma US Inc | $16.07 | 02/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139286902 | CMS |
| Astellas Pharma US Inc | $20.52 | 03/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139296596 | CMS |
| Astellas Pharma US Inc | $21.35 | 10/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139415685 | CMS |
| Exeltis, USA Inc. | $17.27 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150002738 | CMS |
| Genentech, Inc. | $13.60 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133006519 | CMS |
| MAYNE PHARMA COMMERCIAL LLC | $27.68 | 12/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154670555 | CMS |
| Novo Nordisk Inc | $14.84 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096989028 | CMS |
| Organon Llc | $22.49 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136289152 | CMS |
| PFIZER INC. | $16.18 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131403607 | CMS |
| PFIZER INC. | $21.01 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131636952 | CMS |
| PFIZER INC. | $17.52 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131636956 | CMS |
| PFIZER INC. | $19.43 | 11/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131223411 | CMS |
| Sage Therapeutics, Inc. | $22.69 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120393184 | CMS |
| Sumitomo Pharma America, Inc. | $26.47 | 03/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148908306 | CMS |
| Sumitomo Pharma America, Inc. | $15.19 | 12/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148908308 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.